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Background: Vanishing bile duct syndrome has been associated with different pathologic conditions (adverse
drug reactions, autoimmune diseases, graft versus host disease, and cancer). Though its causes are unknown, an
immune-related pathogenesis is the most likely one. Vanishing bile duct syndrome can evolve to hepatic failure and,
eventually, to death. The treatment is uncertain, but it needs the resolution of the underlying pathologic condition.
Case presentation: We describe the association of Hodgkin’s lymphoma with a syndrome characterized by cholestasis,
aminotransferase elevation and an histological picture of bile duct loss. All other causes of hepatic function impairment
were excluded (in particular, drugs, viral and autoimmune related diseases) eventually leading to the diagnosis of
vanishing bile duct syndrome. Despite the fact that the dysfunction is not caused by hepatic Hodgkin’s lymphoma
involvement, liver impairment can limit the optimal therapy of Hodgkin’s lymphoma. A treatment consisting of
ursodeoxycholic acid, prednisone, and full dose chemotherapy restored hepatic function and achieved complete and
long-lasting remission of Hodgkin’s lymphoma.
Conclusion: We reviewed all case reports showing that vanishing bile duct syndrome is a dismal paraneoplastic
syndrome being fatal in a high proportion of patients if not adequately treated. Indeed, this syndrome requires both an
early recognition and an appropriate aggressive treatment consisting of full dose upfront chemotherapy which is the
only way to achieve a resolution of the vanishing bile duct syndrome. Delayed or reduced intensity treatments
unfavorably correlate with survival.
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syndromeBackground
Vanishing bile duct syndrome (VBDS) is defined as an
intrahepatic cholestasis with paucity of interlobular bile
ducts [1]. The cause is unknown and it has been associated
with different pathologic conditions: adverse drug reac-
tions, autoimmune diseases, graft versus host disease, and
cancer. These associations make the immune-mediated* Correspondence: giovanni.grignani@ircc.it
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article, unless otherwise stated.pathogenesis the most likely one. Histology is characterized
by marked cholestasis without evidences of an accompany-
ing hepatitis, but with a characteristic loss of bile ducts in
the portal tracts. Clinical outcome is hepatic failure unless
the underlying disease can be appropriately cured. We
present a case of a VBDS that heralded the successive diag-
nosis of Hodgkin’s lymphoma (HL).Case presentation
A 42-year-old Caucasian woman was admitted to an in-
fectious disease unit because of jaundice and fever. HerCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Paraffin embedded section of the liver biopsy stained
in hematoxylin-eosin showing fibrotic portal spaces without
evidence of biliary interlobular ducts. (Panel A 5x magnification,
Panel B 20x magnification, Panel C 40x magnification).
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allergy to cat hair. On admission her abnormal chemical
tests were: total and direct bilirubin of 18.3 milligrams/
deciliter (mg/dL) and 15.3 mg/dL, respectively (normal
value up to 1.3 and 0.4 mg/dL, respectively); aspartate
(AST) and alanine aminotransferase (ALT), 151 and 322,
respectively (normal value up to 35 units/liter (U/L) and
40 U/L, respectively); alkaline phosphatase (ALP) 322 U/L
(normal value up to 240 U/L); gamma-glutamyl transpep-
tidase (GGT) 482 U/L (normal value up to 35 U/L). Blood
counts were normal except for leukocytosis (15170/μL).
The patient was not taking any drug, and an extensive in-
fectious disease work-up was negative. Particularly, hepa-
totropic viruses such as hepatitis A virus (HAV), hepatitis
B virus (HBV) and hepatitis C virus (HCV) were excluded
as well as Epstein-Barr virus (EBV) and cytomegalovirus
(CMV). A computed tomography (CT) scan showed en-
larged mediastinal lymph nodes without any abdominal
pathological feature, and no sign of biliary tract dilatation.
At that time, the patient was referred to our center, and a
mediastinal biopsy was performed showing a picture of
classic HL of nodular sclerosis histotype. Furthermore, the
most common antibodies responsible for autoimmune
hepatitis (ANA - antinuclear antibodies, ASMA – anti-
smooth-muscle antibodies, anti-LKM1 – anti-liver-
kidney microsomal type 1, anti-SLA - antibodies against
soluble liver antigen, AMA - antimitochondrial antibody,
antiphospholipid antibodies) were evaluated without any
pathological findings. Since biochemical cholestasis had
worsened (total bilirubin 33.8 mg/dL), a hepatic biopsy was
performed showing marked cellular and canalicular perive-
nous cholestasis. Remarkably, bile ducts were absent
(Figure 1) in all seven portal tracts examined and no sign of
HL could be detected in a picture consistent with a VBDS
[1]. Bone marrow trephine was negative. We also carried
out a positron emission tomography (PET) scan that
showed increased 18 F-fluoro-deoxy-glucose (18 F-FDG)
uptake in multiple mediastinal lymph nodes defining a
stage IIB HL. She was started on ursodeoxycholic acid
(UDCA) (1350 mg daily) and prednisone (50 mg daily). A
dramatic improvement of her clinical and biochemical con-
ditions occurred with a decreased total bilirubin to 10 mg/
dL. At this point, doxorubicin, bleomycin, vinblastine and
dacarbazine (ABVD) chemotherapy was delivered and, after
4 cycles, we performed interim restaging with the PET scan
showing a complete response. Therefore, she subsequently
received two additional cycles of ABVD with a complete re-
sponse confirmed after six cycles. Despite the fact that total
bilirubin was increased at the time of the first cycle, we de-
livered a full dose of doxorubicin and vinblastine. At com-
pletion, prednisone was tapered and UDCA interrupted.
The patient declined to receive a hepatic biopsy at the end
of chemotherapy. Six years later, she is still in complete re-
mission with a thoroughly normal hepatic function.Conclusion
Several conditions may cause jaundice in HL. Biliary ob-
struction secondary to lymph nodes enlargement, hemolysis,
hepatotropic and other viruses (e.g. CMV) are among the
most common causes. Hepatic direct involvement by HL is
a relatively rare, but well known complication [2]. The asso-
ciation of cholestatic jaundice and hepatic bile duct loss (a
picture called “ductopenia”) in HL has been described in
other 39 other cases in the literature (Table 1). This is a
Table 1 Summary of all cases reported in the literature regarding vanishing bile duct syndrome in lymphomas
Author Number ofpatients
Hodgkin lymphoma
treatment* Dosage Ursodeoxycholic acid Outcome
Bouroncle B. [9] 2 Yes Full Unknown Hepatic failure
Yes Reduced Hepatic failure
Juniper K. [10] 1 Yes Reduced Unknown Hepatic failure
Groth C. [11] 1 Yes Full Unknown Hepatic failure
Perera D.R. [12] 3 Yes Full Unknown Hepatic failure
Yes Full Unknown Cure
Yes Full Unknown Cure
Piken E.P. [13] 1 Yes Full Unknown Unknown
Trewby P.N. [14] 4 Yes Full Unknown Cure
Yes Full Unknown Cure
Yes Full Unknown Unknown
No No Unknown Unknown
Lieberman D.A. [15] 1 No No No Respiratory arrest
Birrer M.J. [16] 1 Yes Full Unknown Sepsis
Hubscher S.G. [1] 3 Yes Reduced No Hepatic failure
Jansen P.L.M. [17] 1 Yes Full Late Hepatic failure
Warner A.S. [18] 1 Yes Full No Cure
Gottrand F. [19] 1 No No No Hepatic failure
Crosbie O.M. [20] 1 Yes Full Yes Cure
De Medeiros B.C. [21] 2 Yes Full No Hepatic failure
Full
Yalcin S. [22] 2 No No No Hepatic failure
Yes Full No Cure
Dourakis S.P. [23] 1 Yes Reduced No Hepatic failure
Yusuf M.A. [24] 1 No No Late Hepatic failure
Rossini M.S. [25] 1 Yes Full No Hepatic failure
Allory Y. [3] 1 Yes Full Yes Cure
Ozkan A. [26] 1 No No Late Hepatic failure
Ripoll C. [27] 2 Yes Full No Hepatic failure
Yes Full Yes Cure
Komurcu S. [28] 1 Yes Full No Hepatic failure
Liangpunsakul S. [29] 1 Yes Full No Cure
Guliter S. [30] 1 Yes Full Late Hepatic failure
Córdoba Iturriagagoitia A. [31] 1 Yes Full No Cure
Han W.S. [32] 1 No No No Recurrent Hodgkin’s Lymphoma
Schmitt A. [33] 1 No No No Hepatic failure
Barta S.K. [34] 1 Yes Full No Cure
DeBenedet A.T. [35] 1 Yes Reduced No Hepatic failure
Leeuwenburgh I. [36] 1 Yes Reduced No Cure
Pass A.K. [37] 2 Yes Reduced Yes Cure
Yes Reduced No Hepatic failure
Ballonoff A. [38] 1 Yes Full No Cure
Umit H. [39] 1 Unknown Unknown Unknown Unknown
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Table 1 Summary of all cases reported in the literature regarding vanishing bile duct syndrome in lymphomas
(Continued)
Gill R.M. [40] 1 Yes Reduced No Hepatic failure
Foramiti S. [41] 1 Yes Full Yes Hepatic failure
Gagnon MF [42] 1 Yes Full No Cure
Wong KM [43] 1 Yes Full No Cure
Aleem A1 [44] 1 Yes Full No Hepatic failure
Nader K [45] 1 Yes Full No Hepatic failure
Our patient 1 Yes Full Yes Cure
*either chemotherapy or radiotherapy.
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disease otherwise curable in more than 80% of patients. In
18 HL patients steroid plus lymphoma treatment (both
chemotherapy and radiotherapy) was described to im-
prove hepatic function and eventually led to complete re-
mission of both hepatic and Hodgkin’s diseases. All other
cases died because of hepatic failure. A clear pathogenetic
relationship between HL and VBDS cannot be identified.
Nevertheless, the concomitance of the two diseases and
the case reported by Allory [3] makes the hypothesis of
VBDS likely to be a paraneoplastic manifestation of HL.
Furthermore, Bruguera [4] has shown hepatic sinusoidal
dilatation (a feature of VBDS) in 90% of patients present-
ing systemic symptoms (so called B symptoms) without
any evidence of direct liver involvement by the lymphoma.
This datum suggests the role of HL as the trigger event of
cytokine-mediated hepatic damage [5]. There is evidence
that biliary epithelial cells [6] express major histocompati-
bility complex (MHC) antigens (both class I and II) as well
as adhesion molecules like intercellular adhesion molecule
1 (ICAM-1) in response to cytokines produced by HL. In
this context, both types of molecules may contribute to
adhesion and cytotoxicity due to T lymphocytes. As of
today, there is no recognized treatment for VBDS. We, as
well as other authors, used UDCA because of its demon-
strated activity in primary biliary cirrhosis. Indeed, benefi-
cial effects of treatment with UDCA have been reported
in other immune-mediated disease involving the biliary
tree as primary sclerosing cholangitis [7] or hepatic in-
volvement by graft versus host disease [8]. UDCA acts at
three levels: increasing the expression of transporter pro-
teins into the canalicular membrane, inhibiting apoptosis
induced by toxic bile acids, and altering the composition
of the micelles of bile acids [7].
In the present report we stress two aspects. First, the
therapeutic choice to use high-dose of UDCA [46] and
prednisone which rapidly determined an improvement
of our patients. Secondly, although still icteric, we deliv-
ered a full dose chemotherapy achieving a sustained
complete remission that, in a paraneoplastic disease, is
the most important result. An appropriate aggressive
treatment (either chemotherapy or radiotherapy) wasreported in all patients who were, in the end, cured
(Table 1). Notwithstanding, several good reasons stand for
a dose reduction in both doxorubicin and vinblastine in a
jaundiced patient, we emphasize the “full dose” chemother-
apy choice. ABVD chemotherapy is conceived as a 2-
weekly treatment and, therefore, 25 mg/m2 doxorubicin
was felt appropriate regardless of jaundice. Indeed, it is half
the dose used in other combinations (e.g. CHOP regimen -
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
or CODOX-M/IVAC – Cyclophosphamide, Vincristine,
Doxorubicin, Methotrexate, Ifosfamide, Etoposide, Cytara-
bine [47,48]). Moreover, it is well known that the ABVD
dose intensity affects the HL outcome [49,50]. Lastly, only
1 out of 8 (12%) patients receiving an upfront reduced
chemotherapy overcame the vanishing bile duct, compared
to 51% (17/33) of patients treated with upfront full dose
chemotherapy (see Table 1). In these patients the efficacious
treatment of the lymphoma preceded the hepatic improve-
ment and, ultimately, the cure.
This case report demonstrates that in the presence of
a histological diagnosis of HL associated with signs of
cholestasis and liver function impairment without gross
liver involvement or biliary tract dilatation, the prompt
treatment of the underlying disease in association with
high doses of UDCA is crucial. Indeed, data available in
the literature strengthen the theory that the therapy able
to restore liver function is full dose chemotherapy only.
In this setting, waiting for the histological confirmation
of VBDS may be harmful because a delayed start might
be detrimental to patient outcome. Indeed, liver impair-
ment could evolve to liver insufficiency and eventually
to death as is clearly outlined in Table 1.
In conclusion, VBDS must be considered a rare but
possible complication of HL. Its prompt recognition and
appropriate treatment can dramatically affect patients’
outcome.
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